Merck to buy VC-backed VelosBio for $2.75bn
Merck has agreed to acquire VelosBio Inc, a portfolio company of Pappas Capital, for $2.75 billion in cash.
Merck has agreed to acquire VelosBio Inc, a portfolio company of Pappas Capital, for $2.75 billion in cash.
Copyright PEI Media
Not for publication, email or dissemination